A Biopharma Downturn or Return to Trend
Murray Aitken, executive director of the IQVIA Institute for Human Data Science, discusses his organization’s new report on what happened to the biopharmaceutical sector in 2022, how to make sense of the data, and the shifting landscape in therapeutic and geographic investments.